Neuraltus, in partnership with the John A. Burns School of Medicine, University of Hawaii at Manoa, is conducting a Phase 1 placebo-controlled biomarker study of NP001 in patients with mild-to-moderate Alzheimer’s disease. The study is designed to determine the impact of NP001 on the level of systemic inflammation, which is believed to be a contributing factor to disease progression in some neurodegenerative diseases. If the study shows a reduction in inflammation levels, further clinical research may be considered. For more information on the Phase 1 study of NP001 in AD patients, visit https://clinicaltrials.gov.
NP001 is an investigational therapy and the only highly purified, intravenous formulation of sodium chlorite, which is not comparable to oral sodium chlorite. Additional information about oral sodium chlorite, and the potentially dangerous and toxic side-effects, which may hasten disease progression, can be found in a warning from the FDA and ALSUntangled article. Neuraltus does not recommend the use of oral sodium chlorite.